Shanna Babalonis1, Margaret Haney2, Robert J Malcolm3, Michelle R Lofwall4, Victoria R Votaw5, Steven Sparenborg6, Sharon L Walsh4. 1. University of Kentucky, Department of Behavioral Science, Center on Drug and Alcohol Research, Lexington, KY, USA. Electronic address: babalonis@uky.edu. 2. Columbia University Medical Center, Division on Substance Abuse, New York State Psychiatric Institute and the Department of Psychiatry, New York, NY, USA. 3. Medical University of South Carolina, Charleston, SC, USA. 4. University of Kentucky, Department of Behavioral Science, Center on Drug and Alcohol Research, Lexington, KY, USA. 5. McLean Hospital, Division of Alcohol and Drug Abuse, Belmont, MA, USA. 6. National Institute on Drug Abuse, Bethesda, MD, USA.
Abstract
BACKGROUND:Cannabidiol (CBD) is a naturally occurring constituent of the marijuana plant. In the past few years, there has been great interest in the therapeutic effects of isolated CBD and it is currently being explored for numerous disease conditions (e.g., pain, epilepsy, cancer, various drug dependencies). However, CBD remains a Schedule I drug on the U.S. Controlled Substances Act (CSA). Despite its status, there are no well-controlled data available regarding its abuse liability. METHODS:Healthy, frequent marijuana users (n=31) were enrolled in this within subject, randomized, placebo-controlled, double-blind, multisite study that administered oral cannabidiol (0, 200, 400, 800mg) alone and in combination with smoked marijuana (0.01%, 5.3-5.8% THC). Participants received one dose combination across 8 once-weekly outpatient sessions (7.5h). The primary findings on the drug interaction effects were previously reported (Haney et al., 2016). The present study is a secondary analysis of the data to examine the abuse liability profile of oral cannabidiol (200, 400, 800mg) in comparison to oral placebo and active smoked marijuana (5.3-5.8% THC). RESULTS: Active marijuana reliably produced abuse-related subjective effects (e.g., high) (p<0.05). However, CBD was placebo-like on all measures collected (p>0.05). CONCLUSIONS: Overall, CBD did not display any signals of abuse liability at the doses tested and these data may help inform U.S. regulatory decisions regarding CBD schedule on the CSA.
RCT Entities:
BACKGROUND:Cannabidiol (CBD) is a naturally occurring constituent of the marijuana plant. In the past few years, there has been great interest in the therapeutic effects of isolated CBD and it is currently being explored for numerous disease conditions (e.g., pain, epilepsy, cancer, various drug dependencies). However, CBD remains a Schedule I drug on the U.S. Controlled Substances Act (CSA). Despite its status, there are no well-controlled data available regarding its abuse liability. METHODS: Healthy, frequent marijuana users (n=31) were enrolled in this within subject, randomized, placebo-controlled, double-blind, multisite study that administered oral cannabidiol (0, 200, 400, 800mg) alone and in combination with smoked marijuana (0.01%, 5.3-5.8% THC). Participants received one dose combination across 8 once-weekly outpatient sessions (7.5h). The primary findings on the drug interaction effects were previously reported (Haney et al., 2016). The present study is a secondary analysis of the data to examine the abuse liability profile of oral cannabidiol (200, 400, 800mg) in comparison to oral placebo and active smoked marijuana (5.3-5.8% THC). RESULTS: Active marijuana reliably produced abuse-related subjective effects (e.g., high) (p<0.05). However, CBD was placebo-like on all measures collected (p>0.05). CONCLUSIONS: Overall, CBD did not display any signals of abuse liability at the doses tested and these data may help inform U.S. regulatory decisions regarding CBD schedule on the CSA.
Authors: Luciano De Petrocellis; Alessia Ligresti; Aniello Schiano Moriello; Marco Allarà; Tiziana Bisogno; Stefania Petrosino; Colin G Stott; Vincenzo Di Marzo Journal: Br J Pharmacol Date: 2011-08 Impact factor: 8.739
Authors: Sagnik Bhattacharyya; Paul D Morrison; Paolo Fusar-Poli; Rocio Martin-Santos; Stefan Borgwardt; Toby Winton-Brown; Chiara Nosarti; Colin M O' Carroll; Marc Seal; Paul Allen; Mitul A Mehta; James M Stone; Nigel Tunstall; Vincent Giampietro; Shitij Kapur; Robin M Murray; Antonio W Zuardi; José A Crippa; Zerrin Atakan; Philip K McGuire Journal: Neuropsychopharmacology Date: 2009-11-18 Impact factor: 7.853
Authors: Michal Tzadok; Shimrit Uliel-Siboni; Ilan Linder; Uri Kramer; Orna Epstein; Shay Menascu; Andrea Nissenkorn; Omer Bar Yosef; Eli Hyman; Dorit Granot; Michael Dor; Tali Lerman-Sagie; Bruria Ben-Zeev Journal: Seizure Date: 2016-01-06 Impact factor: 3.184
Authors: J M Cunha; E A Carlini; A E Pereira; O L Ramos; C Pimentel; R Gagliardi; W L Sanvito; N Lander; R Mechoulam Journal: Pharmacology Date: 1980 Impact factor: 2.547
Authors: Tom P Freeman; Celia J A Morgan; Chandni Hindocha; Gráinne Schafer; Ravi K Das; H Valerie Curran Journal: Addiction Date: 2014-07-16 Impact factor: 6.526
Authors: Mallory J E Loflin; Brian D Kiluk; Marilyn A Huestis; Will M Aklin; Alan J Budney; Kathleen M Carroll; Deepak Cyril D'Souza; Robert H Dworkin; Kevin M Gray; Deborah S Hasin; Dustin C Lee; Bernard Le Foll; Frances R Levin; Joshua A Lile; Barbara J Mason; Aimee L McRae-Clark; Ivan Montoya; Erica N Peters; Tatiana Ramey; Dennis C Turk; Ryan Vandrey; Roger D Weiss; Eric C Strain Journal: Drug Alcohol Depend Date: 2020-04-26 Impact factor: 4.492
Authors: Marcel O Bonn-Miller; Mallory J E Loflin; Brian F Thomas; Jahan P Marcu; Travis Hyke; Ryan Vandrey Journal: JAMA Date: 2017-11-07 Impact factor: 56.272
Authors: Douglas L Boggs; Jacques D Nguyen; Daralyn Morgenson; Michael A Taffe; Mohini Ranganathan Journal: Neuropsychopharmacology Date: 2017-09-06 Impact factor: 7.853
Authors: Brian D Klein; Catherine A Jacobson; Cameron S Metcalf; Misty D Smith; Karen S Wilcox; Aidan J Hampson; John H Kehne Journal: Neurochem Res Date: 2017-05-06 Impact factor: 3.996
Authors: Dennis J Sholler; Marilyn A Huestis; Benjamin Amendolara; Ryan Vandrey; Ziva D Cooper Journal: Pharmacol Biochem Behav Date: 2020-10-18 Impact factor: 3.533